{
  "alleleExist":true,
  "dataVersion":"v4.5",
  "diagnosticImplications":[],
  "diagnosticSummary":"",
  "geneExist":true,
  "geneSummary":"CTNNB1 (\u03b2-catenin), a transcriptional activator, is recurrently mutated in various cancers including endometrial and hepatocellular cancers.",
  "highestDiagnosticImplicationLevel":null,
  "highestFdaLevel":null,
  "highestPrognosticImplicationLevel":null,
  "highestResistanceLevel":null,
  "highestSensitiveLevel":null,
  "hotspot":true,
  "lastUpdate":"11/23/2020",
  "mutationEffect":{
    "citations":{
      "abstracts":[],
      "pmids":[
        "21060032",
        "15829978",
        "16160475",
        "12708483",
        "22832583"
      ]
    },
    "description":"The CTNNB1 D32A mutation is located in the N-terminus of the protein. This mutation has been found in endometrial, liver and brain cancer (PMID: 21060032, 22832583, 16160475, 12708483). Expression of the D32A mutant in a canine kidney cell line demonstrated that it is activating as measured by increased cell invasion and three-dimensional growth compared to wildtype (PMID: 15829978).",
    "knownEffect":"Gain-of-function"
  },
  "oncogenic":"Likely Oncogenic",
  "otherSignificantResistanceLevels":[],
  "otherSignificantSensitiveLevels":[],
  "prognosticImplications":[],
  "prognosticSummary":"",
  "query":{
    "alteration":"D32A",
    "alterationType":null,
    "consequence":null,
    "entrezGeneId":1499,
    "hgvs":null,
    "hugoSymbol":"CTNNB1",
    "id":null,
    "proteinEnd":null,
    "proteinStart":null,
    "referenceGenome":"GRCh38",
    "svType":null,
    "tumorType":null
  },
  "treatments":[],
  "tumorTypeSummary":"",
  "variantExist":true,
  "variantSummary":"The CTNNB1 D32A mutation is likely oncogenic.",
  "vus":false
}